Why Is NUVATION BIO INC A Class A (NUVB) Stock Moving Today?

Why NUVB stock is up today

Nuvation Bio Inc. (NUVB) rose 7.41% to $6.96 on Monday, driven by a new initiation of coverage from J.P. Morgan. The firm assigned the stock an Overweight rating, citing a strong launch trajectory for the company’s lead drug, Ibtrozi. This move has drawn attention from multiple financial analysts and is reflected in a broader coverage shift toward the stock.

What Happened

J.P. Morgan initiated coverage of Nuvation Bio with an Overweight rating, signaling confidence in the company’s near-term prospects. The firm highlighted the potential of Ibtrozi, a targeted cancer therapy, and its expected market entry. This followed similar positive ratings from RBC Capital and HC Wainwright & Co., which also raised price targets for the stock. Nuvation Bio recently reported second-quarter results that beat revenue and EPS estimates, adding to the positive momentum. The company also announced that new data from its Phase 2 trials for Ibtrozi in ROS1+ NSCLC will be presented at major oncology conferences, including WCLC and ESMO.

What The Data Shows

Nuvation Bio’s stock has shown mixed performance over the past eight sessions, falling 5.0% from $6.37 to $6.05 before Monday’s sharp rebound. The stock currently trades within its 52-week range of $2.57 to $9.75. On August 19, the stock printed 14 fresh 52-week highs and 15 fresh 52-week lows, indicating heightened volatility. Recent insider transactions show three separate sales totaling $1.4 million by senior executives, including the CFO, Chief People Officer, and Chief Regulatory Officer. These sales occurred on June 23, 2026, and were reported via SEC Form 4. Over the last 90 days, insiders have sold $1.4 million in shares, while only $118,000 worth of shares were purchased.

What To Watch

Nuvation Bio is not scheduled to report earnings in the near term. Investors should monitor the breadth of analyst coverage and any updates on the regulatory or clinical progress of Ibtrozi, particularly ahead of its presentation at WCLC and ESMO.